Candidiasis - Do we need to fight or to tolerate the Candida fungus?

Folia Microbiologica

Volumn 52, Issue 3, 2007, Pages 297-312

  Raska M ^a   Belakova J ^a   Krupka M ^a   Weigl, E ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA; FUNGI;

EID: 34547261700     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02931313     Document Type: Review

References (87)

1. + cells also demonstrate strain-specific immunopathological effects. Microbiology 145, 1631-1640 (1999).
2. ASHMAN R.B., PAPADIMITRIOU J.M., FULURIJA A., DRYSDALE K.E., FARAH C.S., NAIDOO O., GOTJAMANOS T.: Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb.Pathog. 34, 103-113 (2003).
3. BAROUSSE M.M., STEELE C., DUNLAP K., ESPINOSA T., BOIKOV D., SOBEL J.D., FIDEL P.L. Jr.: Growth inhibition of Candida albicans by human vaginal epithelial cells. J.Infect.Dis. 184, 1489-1493 (2001).
4. BAROUSSE M.M., VAN DER POL B.J., FORTENBERRY D., ORR D., FIDEL P.L. Jr.: Vaginal yeast colonization, prevalence of vaginitis, and associated local immunity in adolescents. Sex.Transm.Infect. 80, 48-53 (2004).
5. BELLOCCHIO S., MONTAGNOLI C., BOZZA S., GAZIANO R., ROSSI G., MAMBULA S.S., VECCHI A., MANTOVANI A., LEVITZ S.M., ROMANI L.: The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J.Immunol. 172, 3059-3069 (2004).
6. BENINATI C., OGGIONI M.R., BOCCANERA M., SPINOSA M.R., MAGGI T., CONTI S., MAGLIANI W., DE BERNARDIS F., TETI G., CASSONE A., POZZI G., POLONELLI L.: Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nature Biotechnol. 18, 1060-1064 (2000).
7. BIALKOVÁ A., ŠUBÍK J.: Biology of the pathogenic yeast Candida glabrata. Folia Microbiol. 51, 3-20 (2006).
8. BLACK C.A., ROHAN L.C., COST M., WATKINS S.C., DRAVIAM R., ALBER S., EDWARDS R.P.: Vaginal mucosa serves as an inductive site for tolerance. J.Immunol. 165, 5077-5083 (2000).
9. CALDERONE R.A., FONZI W.A.: Virulence factors of Candida albicans. Trends Microbiol. 9, 327-335 (2001).
10. DE CARVALHO R.J., CUNHA C.M., SILVA D.A., SOPELETE M.C., URZEDO J.E., MOREIRA T.A., MORAES PDE S., TAKETOMI E.A.: IgA, IgE and IgG subclasses to Candida albicans in serum and vaginal fluid from patients with vulvovaginal candidiasis. Rev. Assoc.Med.Brasil 49, 434-438 (2003).
11. CASSONE A., PALMA C., DJEU J.Y., AIUTI F., QUINTI I.: Anti-Candida activity and interleukin-1β and interleukin-6 production by polymorphonuclear leukocytes are preserved in subjects with AIDS. J.Clin.Microbiol. 31, 1354-1357 (1993).
12. CASSONE A., DE BERNARDIS F., TOROSOSANTUCCI A.: An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr.Mol.Med. 5, 377-382 (2005).
13. CENCI E., ROMANI L., MENCACCI A., SPACCAPELO R., SCHIAFFELLA E., PUCCETTI P., BISTONI F.: Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans, Eur.J.Immunol. 23, 1034-1038 (1993).
14. CHEN Y., KUCHROO V.K., INOBE J., HAFLER D.A., WEINER H.L.: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
15. CLAUDIA M., BACCI A., SILVIA B., GAZIANO R., SPRECA A., ROMANI L.: The interaction of fungi with dendritic cells: implications for TH immunity and vaccination. Curr.Mol.Med. 2, 507-524 (2002).
16. CUTLER J.E.: Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice. J.Reticuloendothel.Soc. 19, 121-124 (1976).
17. CUTLER J.E.: Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr.Mol.Med. 5, 383-392 (2005).
18. DE BERNARDIS F., BOCCANERA M., ADRIANI D., SPREGHINI E., SANTONI G., CASSONE A.: Protective role of antimannan and antiaspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect.Immun. 65, 3399-3405 (1997).
19. DE BERNARDIS F., BOCCANERA M., ADRIANI D., GIROLAMO A., CASSONE A.: Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect.Immun. 70, 2725-2729 (2002).
20. DEEPE G.S.Jr.: Prospects for the development of fungal vaccines. Clin.Microbiol.Rev. 10, 585-596 (1997).
21. DJEU J.Y., SERBOUSEK D., BLANCHARD D.K.: Release of tumor necrosis factor by human polymorphonuclear leukocytes. Blood 76, 1405-1409 (1990).
22. DONGARI-BAGTZOGLOU A., FIDEL P.L. Jr.: The host cytokine responses and protective immunity in oropharyngeal candidiasis. J.Dent. Res. 84, 966-977 (2005).
23. DORKO E., PILIPČINEC E., TKÁČ IKOVÁ L'.: Fungal diseases of the respiratory tract. Folia Microbiol. 47, 302-304 (2002a).
24. DORKO E., PILIPČINEC E., TKÁČ IKOVÁ L'.: Candida urinary tract infections caused by non-albicans Candida species. Folia Microbiol. 47, 182-184 (2002b).
25. DORKO E., PILIPČINEC E., TKÁČ IKOVÁ L'.: Candida species isolated from cerebrospinal fluid. Folia Microbiol. 47, 179-181 (2002c).
26. DORKO E., BARANOVÁ Z., JENČA A., KIZEK P., PILIPČINEC E., TKÁČ IKOVÁ L'.: Diabetes mellitus and candidiases. Folia Microbiol. 50, 255-262 (2005).
27. ELAHI S., PANG G., CLANCY R., ASHMAN R.B.: Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis. Infect.Immun. 68, 5771-5777 (2000).
28. + T lymphocytes in recovery from oropharyngeal candidiasis. Infect.Immun. 70, 724-731 (2002).
29. FIDEL P.L. Jr.: Distinct protective host defenses against oral and vaginal candidiasis. Med.Mycol. 40, 359-375 (2002a).
30. FIDEL P.L. Jr.: Immunity to Candida. Oral.Dis. 8 (Suppl. 2), 69-75 (2002b).
31. FIDEL P.L. Jr.: Immunity in vaginal candidiasis. Curr.Opin.Infect.Dis. 18, 107-111 (2005).
32. FIDEL P.L. Jr., SOBEL J.D.: Protective immunity in experimental Candida vaginitis. Res.Immunol. 149, 361-373 (1998).
33. FIDEL P.L. Jr., LYNCH M.E., SOBEL J.D.: Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect.Immun. 63, 2403-2408 (1995).
34. FIDEL P.L. Jr., WOLF N.A., KUKURUGA M.A.: T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect.Immun. 64, 3793-3799 (1996).
35. FIDEL P.L. Jr., WORMLEY F.L. Jr., CHAIBAN J., CHESSON R.R., LOUNF.V V.: Analysis of the CD4 protein on human vaginal T lymphocytes. Am.J.Reprod.Immunol. 45, 200-204 (2001).
36. FIDEL P.L. Jr., BAROUSSE M., ESPINOSA T., FICARRA M., STURTEVANT J., MARTIN D.H., QUAYLE A.J., DUNLAP K.: An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect. Immun. 72, 2939-2946 (2004).
37. FRIEDMAN A., WEINER H.L.: Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Nat.Acad.Sci.USA 91, 6688-6692 (1994).
38. FULURIJA A., ASHMAN R.B., PAPADIMITRIOU J.M.: Increased tissue resistance in the nude mouse against Candida albicans without altering strain-dependent differences in susceptibility. J.Med. Vet.Mycol. 35, 197-203 (1997).
39. GUDLAUGSSON O., GLLLESPIE S., LEE K., VANDE BERG J., HU J., MESSER S., HERWALDT L., PFALLER M., DIEKEMA D.: Attributable mortality of nosocomial candidemia, revisited. Clin.Infect.Dis. 37, 1172-1177 (2003).
40. HAN Y., CUTLER J.E.: Antibody response that protects against disseminated candidiasis. Infect.Immun. 63, 2714-2719 (1995).
41. HAN Y., MORRISON R.P., CUTLER J.E.: A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect.Immun. 66, 5771-5776 (1998).
42. JÍLEK P., ŠPAČEK J., BUCHTA V., KUČERA Z., DRAHOŠOVÁ M., FÖRSTL M., ANDRÝS C.: Systemic immunity in patients with recurrent vulvovaginal candidiasis. Česká Gynekol. 70, 453-454 (2005).
43. JOHANSEN F.E., BRANDTZAEG P.: Transcriptional regulation of the mucosal IgA system. Trends Immunol 25, 150-157 (2004).
44. KALKANCI A., TUNCER C., DEGERTEKIN B., EREN A., KUSTIMUR S., ILHAN M.N., DURSUN A.: Detection of Candida albicans by culture, serology and PCR in clinical specimens from patients with ulcerative colitis: re-evaluation of an old hypothesis with a new perspective. Folia Microbiol. 50, 263-268 (2005a).
45. KALKANCI A., BOZDAYI G., BIRI A., KUSTIMUR S.: Distribution of secreted aspartyl proteinases using a polymerase chain reaction assay with SAP specific primers in Candida albicans isolates. Folia Microbiol. 50, 409-414 (20056).
46. KAPOSZTA R., MARODI L., HOLLINSHEAD M., GORDON S., DA SILVA R.P.: Rapid recruitment of late endosomes and lysosomes in mouse macrophages ingesting Candida albicans. J.Cell.Sci. 112, 3237-3248 (1999).
47. KIRKPATRICK C.H.: Chronic mucocutaneous candidiasis. Pediatr.Infect.Dis.J. 20, 197-206 (2001).
48. KOZEL T.R., WEINHOLD L.C., LUPAN D.M.: Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect.Immun. 64, 3360-3368 (1996).
49. LEIGH J.E., BAROUSSE M., SWOBODA R.K., MYERS T., HAGER S., WOLF N.A., CUTRIGHT J.L., THOMPSON J., SOBEL J.D., FIDEL P.L. Jr.: Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J.Infect.Dis. 183, 277-285 (2001).
50. LITTLE C.H., GEORGIOU G.M., MARCEGLIA A., OGEDGEBE H., CONE R.E., MAZZA D.: Measurement of T-cell-derived antigen binding molecules and immunoglobulin G specific to Candida albicans mannan in sera of patients with recurrent vulvovaginal candidiasis. Infect.Immun. 68, 3840-3847 (2000).
51. MAGLIANI W., CONTI S., ARSENI S., SALATI A., RAVANETTI L., MAFFEI D.L., GIOVATI L., POLONELLI L.: Antibody-mediated protective immunity in fungal infections. New Microbiol. 28, 299-309 (2005a).
52. MAGLIANI W., CONTI S., FRAZZI R., RAVANETTI L., MAFFEI D.L., POLONELLI L.: Protective antifungal yeast killer toxin-like antibodies. Curr.Mol.Med. 5, 443-452 (2005b).
53. MATTHEWS R.C., BURNIE J.P.: Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 22, 865-871 (2004).
54. MATTHEWS R.C., BURNIE J.P.: Human recombinant antibody to Hsp90: a natural partner in combination therapy. Curr.Mol.Med. 5, 403-411 (2005).
55. MIYAKE T., TAKEYA K., NOMOTO K., MURAOKA S.: Cellular elements in the resistance to Candida infection in mice - I. Contribution of T lymphocytes and phagocytes at various stages of infection. Microbiol.Immunol. 21, 703-725 (1977).
56. +)-T-Cell-mediated resistance to systemic murine candidiasis induced by a membrane fraction of Candida albicans. Antimicrob.Agents Chemother. 44, 2653-2658 (2000).
57. MORGAN J., MELTZER M.I., PLIKAYTIS B.D., SOFAIR A.N., HUIE-WHITE S., WILCOX S., HARRISON L.H., SEABERG E.C., HAJJEH R.A., TEUTSCH S.M.: Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect.Control.Hosp.Epidemiol. 26, 540-547 (2005).
58. NOMANBHOY F., STEELE C., YANO J., FIDEL P.L. Jr.: Vaginal and oral epithelial cell anti-Candida activity. Infect.Immun. 70, 7081-7088 (2002).
59. OMAETXEBARRIA M.J., MORAGUES M.D., ELGUEZABAL N., RODRIGUEZ-ALEJANDRE A., BRENA S., SCHNEIDER J., POLONELLI L., PONTON J.: Antifungal and antitumor activities of a monoclonal antibody directed against a stress mannoprotein of Candida albicans. Curr.Mol.Med. 5, 393-401 (2005).
60. PACHL J., SVOBODA P., JACOBS F., VANDEWOUDE K., VAN DER HOVEN B., SPRONK P., MASTERSON G., MALBRAIN M., AOUN M., GARBINO J., TAKALA J., DRGONA L., BURNIE J., MATTHEWS R.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin.Infect.Dis. 42, 1404-1413 (2006).
61. PALMA C., SERBOUSEK D., TOROSANTUCCI A., CASSONE A., DJEU J.Y.: Identification of a mannoprbtein fraction from Candida albicans that enhances human polymorphonuclear leukocyte (PMNL) functions and stimulates lactoferrin in PMNL inhibition of Candidal growth. J.Infect.Dis. 166, 1103-1112 (1992).
62. PAPPAS P.G., REX J.H., LEE J., HAMILL R.J., LARSEN R.A., POWDERLY W., KAUFFMAN C.A., HYSLOP N., MANGINO J.E., CHAPMAN S., HOROWITZ H.W., EDWARDS J.E., DISMUKES W.E.: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin.Infect.Dis. 37, 634-643 (2003).
63. POLONELLI L., ARCHIBUSACCI C., SESTITO M., MORACE G.: Killer system: a simple method for differentiating Candida albicans strains. J.Clin. Microbiol. 17, 774-780 (1983).
64. POLONELLI L., LORENZINI R., DE BERNARDIS F., MORACE G.: Potential therapeutic effect of yeast killer toxin. Mycopathologia 96, 103-107 (1986).
65. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J.Exp.Med. 179, 589-600 (1994).
66. RAŠKA M., WEIGL E.: Heat shock proteins in autoimmune diseases. Biomed.Pap.Med.Fac.Univ.Palacký Olomouc Czech Rep. 149, 243-249 (2005).
67. RAŠKA M., BĚLÁKOVÁ J., WUDATTU N.K., KAFKOVÁ L., RŮŽIČ KOVÁ K., ŠEBESTOVÁ M., KOLÁ Ř Z., WEIGL E.: Comparison of protective effect of protein and DNA vaccines Hsp90 in murine model of systemic candidiasis. Folia Microbiol. 50, 77-82 (2005).
68. ROGERS T., BALISH E.: Experimental Candida albicans infection in conventional mice and germfree rats. Infect.Immun. 14, 33-38 (1976).
69. ROMANI L., PUCCETTI P., MENCACCI A., CENCI E., SPACCAPELO R., TONNETTI L., GROHMANN U., BISTONI F.: Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J.Immunol. 152, 3514-3521 (1994).
70. + T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J.Exp.Med. 183, 1345-1355 (1996a).
71. ROMANI L., PUCCETTI P., BISTONI F.: Biological role of TH cell subsets in candidiasis. Chem.Immunol. 63, 115-137 (1996b).
72. ROMANI L., BISTONI F., PUCCETTI P.: Fungi, dendritic cells and receptors: a host perspective of fungal virulence. Trends Microbiol. 10, 508-514(2002).
73. +) T cells and possible participation of other local lymphocyte effectors. Infect.Immun. 70, 4791-4797 (2002).
74. SEGAL E.: Candida, still number one - what do we know and where are we going from there? Mycoses 48 (Suppl. 1), 3-11 (2005).
75. SHOHAM S., LEVITZ S.M.: The immune response to fungal infections. Brit.J.Haematol. 129, 569-582 (2005).
76. STEELE C., LEIGH J., SWOBODA R., FIDEL P.L. Jr.: Growth inhibition of Candida by human oral epithelial cells. J.Infect.Dis. 182, 1479-1485 (2000).
77. SWOBODA R.K., BERTRAM G., BUDGE S., GOODAY G.W., GOW N.A., BROWN A.J.: Structure and regulation of the HSP90 gene from the pathogenic fungus Candida albicans. Infect.Immun. 63, 4506-4514 (1995).
78. TAKEDA K., KAISHO T., AKIRA S.: Toll-like receptors. Ann.Rev.Immunol. 21, 335-376 (2003).
79. TARDIF F., GOULET J.P., ZAKRAZEWSKI A., CHAUVIN P., ROUABHIA M.: Involvement of interleukin-18 in the inflammatory response against oropharyngeal candidiasis. Med.Sci.Monit. 10, BR239-BR249 (2004).
80. TAYLOR B.N., SAAVEDRA M., FIDEL P.L. Jr.: Local TH1/TH2 cytokine production during experimental vaginal candidiasis: potential importance of transforming growth factor β. Med.Mycol. 38, 419-431 (2000).
81. TOROSANTUCCI A., BROMURO C., CHIANI P., DE BERNARDIS F., BERTI F., GALLI C., NORELLI F., BELLUCCI C., POLONELLI L., COSTANTINO P., RAPPUOLI R., CASSONE A.: A novel glyco-conjugate vaccine against fungal pathogens. J.Exp.Med. 202, 597-606 (2005).
82. TUITE A., ELIAS M., PICARD S., MULLICK A., GROS P.: Genetic control of susceptibility to Candida albicans in susceptible A/J and resistant C57BL/6J mice. Genes Immun. 6, 672-682 (2005).
83. WEIGL E., KOPEČEK P., RAŠKA M., HRADILOVÁ S.: Heat shock proteins in immune reactions. Folia Microbiol. 44, 561-566 (1999).
84. WORMLEY F.L. Jr., CHAIBAN J., FIDEL P.L. Jr.: Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis. Infect.Immun. 69, 5072-5079 (2001a).
85. WORMLEY F.L. Jr., STEELE C., WOZNIAK K., FUJIHASHI K., MCGHEE J.R., FIDEL P.L. Jr.: Resistance of T-cell receptor δ-chain-deficient mice to experimental Candida albicans vaginitis. Infect.Immun. 69, 7162-7164 (2001b).
86. WOZNIAK K.L., WORMLEY F.L. Jr., FIDEL P.L. Jr.: Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect. Immun. 70, 5790-5799 (2002).
87. ZAOUTIS T.E., ARGON J., CHU J., BERLIN J.A., WALSH T.J., FEUDTNER C.: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin.Infect.Dis. 41, 1232-1239 (2005).